08 January
2025
ImmuPharma
PLC
("ImmuPharma" or the "Company")
IMMUPHARMA at JP MORGAN
CONFERENCE and BIOTECH SHOWCASE
11-16 JAN 2025, SAN
FRANCISCO
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company, announces that Tim McCarthy, CEO, Dr Tim
Franklin, COO, and Dr Sebastien Goudreau, CEO of the R&D
subsidiary ImmuPharma Biotech will be attending both the JP Morgan
Conference and the Biotech Showcase from 11-16 January 2025, in San
Francisco.
The JP Morgan conference and Biotech
Showcase are annual premier partnering events, designed to provide
biotechnology companies with the opportunity to present to and
connect with global Biopharma companies and investors.
The advances made by ImmuPharma with
the P140 program, particularly in the latter part of 2024, have led
to significant interest from leading Biopharmaceutical companies
and we are progressing discussions as we move to establish
global licensing agreements.
There have been eleven $1bn+ licensing deals for immunology assets across the
BioPharma industry from 2023 to late September 2024. The current
trend suggests that Immunology and Autoimmune drug assets are
becoming very highly sought by the leading BioPharma
companies.
Commenting on this announcement, Tim
McCarthy, CEO of ImmuPharma said: "Attending and taking
meetings at both the JP Morgan conference and the Biotech Showcase
offers the opportunity to continue discussions across our whole
unique portfolio and specifically with global BioPharma companies
that have an interest in autoimmune diseases demonstrated within
our P140 technology platform. Our focus remains on track to
establish global partnering opportunities across all of our
programs."
Ends
|
For further information please
contact:
|
ImmuPharma PLC (www.immupharma.co.uk)
Tim McCarthy, Chief Executive
Officer
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+44 (0) 7721 413496
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368 3550
+44 (0) 20 3650 3650
+44 (0) 1483 413500
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, P140,is a first-in class "immune tolerance
restorer" for the treatment of SLE (Systemic Lupus Erythematosus)
and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and
preclinical models suggest therapeutic activity for many other
autoimmune diseases that share the same mechanism of
action.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
About Reach announcements
Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute media only / non-regulatory news
releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement
is required to be notified under the AIM Rules for
Companies.
